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Syzygium polyanthum Protects Against Hypertensive Induced Kidney Damage in 
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(Perlindungan Syzygium Polyanthum terhadap Penyakit Ginjal Kronik Aruhan Hipertensi dalam              
Model Tikus Berhipertensi Spontan 
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ABSTRACT
Syzygium polyanthum is traditionally used as anti-hypertensive agent. However, the nephroprotective effects of S. 
polyanthum against hypertensive induced chronic kidney disease has yet to be elucidated. This study was conducted to 
determine the antioxidant properties and nephroprotective effects of aqueous extract of S. polyanthum (AESP) in the 
spontaneous hypertensive rat model (SHR). The phytochemical constituent was identified using the phytochemical 
screening and HPLC methods. The in vitro antioxidant activities were determined by DPPH radical scavenging and 
ferric reducing antioxidant power (FRAP) assays. Fifty male SHR were equally divided into 5 groups, (n=10/group); 
Untreated-SHR, 20 mg/kg Losartan-treated SHR, 1500 mg/kg AESP treated SHR, 1750 mg/kg AESP treated SHR and 
2250 mg/kg AESP treated SHR, while 10 male Wistar Kyoto rats (WKY) were used as control. Losartan and AESP were 
administered by oral gavage. Rats were sacrificed after 12 weeks of experiment. The phytochemicals include phenolics, 
flavonoids and alkaloids were identified. AESP has high antioxidant activity as shown by antioxidant assays. AESP 
normalised systolic blood pressure (p<0.05) and significantly improved renal function (p<0.05). AESP also significantly 
reduced malondialdehyde (MDA) (p<0.05) and increased superoxide dismutase (SOD) levels in the serum as compared 
to untreated-SHR group (p<0.05). Ultrastructure of renal damage improved by supplementation of AESP. Conclusively, 
S. polyanthum is potential to alleviate hypertensive induced chronic kidney disease through its antioxidant properties. 
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ABSTRAK
Syzygium polyanthum digunakan secara tradisi sebagai agen anti-hipertensi. Walau bagaimanapun, kesan perlindungan 
pada ginjal dalam penyakit ginjal kronik aruhan hipertensi masih perlu dilakukan. Kajian ini dijalankan untuk 
mengenalpasti pelbagai ciri antioksidan dan kesan perlindungan pada ginjal oleh ekstrak akues S. polyanthum (AESP) 
dalam model tikus berhipertensi spontan (SHR). Komponen fitokimia dikenalpasti menggunakan saringan fitokimia dan 
teknik HPLC. Aktiviti in vitro antioksidan dikenalpasti melalui asai penangkapan radikal bebas DPPH dan asai kuasa 
antioksidan penurunan ferik (FRAP). Lima puluh ekor tikus jantan SHR dibahagikan sama rata kepada 5 kumpulan, 
(n=10/kumpulan); SHR tidak dirawat, SHR dirawat dengan 20 mg/kg Losartan, SHR dirawat dengan 1500 mg/kg 
AESP, SHR dirawat dengan 1750 mg/kg AESP dan SHR dirawat dengan 2250 mg/kg AESP, manakala 10 ekor tikus 
jantan Wistar Kyoto rats (WKY) telah digunakan sebagai kumpulan kawalan. Semua tikus dikorbankan selepas 12 
minggu tempoh eksperimen. Kandungan fitokimia termasuk fenolik, flavonoid dan alkaloid telah dikenal pasti. AESP 
mempunyai aktiviti antioksidan yang tinggi ditunjukkan melalui asai antioksidan. AESP menormalkan tekanan darah 
sistolik dan menambah baik fungsi ginjal dengan signifikan. AESP juga menurunkan aras malondialdehid (MDA) dan 
meningkatkan aras superoksida dismutase (SOD) dalam serum dengan signifikan berbanding kumpulan SHR yang tidak 
dirawat. Histologi ginjal yang rosak dipulihkan dengan suplemen AESP. Kesimpulannya, S. polyanthum boleh digunakan 
untuk mengurangkan penyakit ginjal kronik aruhan hipertensi melalui pelbagai ciri antioksidan. 
Kata kunci: Antioksidan; perlindungan pada ginjal; Syzygium polyanthum; tikus berhipertensi spontan
INTRODUCTION
Hypertension, a chronic increase in blood pressure above 
140/90 mmHg, remains a major health challenge and 
burden worldwide (Whelton et al. 2017; Mahadir Naidu 
et al. 2019). This disease is one of the major public health 
problems with global prevalence which increased from 594 
million to 1.13 billion people in 1975 and 2015 respectively 
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(NCD Risk Factor Collaboration 2017). These numbers 
are expected to remain high by 2025, with approximately 
1.56 billion people will have hypertension (Tabrizi et al. 
2016). Despite government policies and hypertension task 
forces, the prevalence of hypertension in Malaysia has been 
persistently high (Mahadir Naidu et al. 2019). Hypertension 
also contributes to various complications such as stroke, 
myocardial infarction, heart failure, peripheral arterial 
disease and end-stage renal disease, which increase the 
risk of death if not treated early (Adler et al. 2015). Arterial 
hypertension is associated with end-organ damaged, 
including vasculopathy, cerebrovascular damage, heart 
disease and nephropathy (Schmieder 2010). 
Evidence has accumulated that the prevalence of a bi-
directional relationship between hypertension and related 
organ damage is increasing worldwide. Hypertension is 
recognized as a major cause and effect of kidney disease 
(Pugh et al. 2019). Systemic hypertension is known to cause 
glomerular hypertension that manifests as high perfusion 
pressure, high filtration pressure, and high transmembrane 
pressure in glomeruli (Endlich & Endlich 2012). Typically, 
blood pressure (BP) rises with decreased kidney function 
and sustained elevation in BP causes progression of 
kidney disease (Judd & Calhoun 2015). The impact of 
uncontrolled hypertension is mainly associated with several 
renal morphological changes, particularly abnormalities 
in glomerular, renal vessel, renal tubules and interstitial 
tissues disorders (Mullins et al. 2016). Multiple factors 
have been attributed to the pathophysiology of chronic 
kidney disease (CKD) associated hypertension, including 
sodium dysregulation, increased sympathetic nervous 
system and alterations in renin-angiotensin aldosterone 
system activity (Hamrahian & Falkner 2016). Hypertensive 
nephrosclerosis is a common leading cause of end-stage 
renal disease (Hart & Bakris 2010; Murea & Freedman 
2010). 
It is important to control the progression of 
hypertension in patients with renal disease as it slows 
the disease progression (Pugh et al. 2019). The need for 
antihypertensive drugs is not limited only to control blood 
pressure, but also to prevent complications of hypertension 
(Weisfeldt & Zieman 2007). According to the World Health 
Organization, around 80% of the world ‘s population relies 
on herbal products as primary health care (Ekor 2014). It 
has been reported that up to 70,000 plant species have been 
screened for biological activity and about 70% have been 
commercialized (Nordin et al. 2019). The ethno-medicinal 
study of plants continues to expand rapidly throughout 
the world, bringing many new products into the market. 
Syzygium polyanthum (Wight) walp. var. polyanthum or 
commonly referred to as “serai kayu” that belongs to the 
family of Myrtaceae, is one of the medicinal plants that 
has been linked to the treatment of hypertension. The 
plant is commonly distributed in tropical regions of Asian 
countries, including Malaysia (Ismail & Wan Ahmad 2019), 
Indonesia (Widyawati et al. 2015), Thailand (Suksri et al. 
2005) and Singapore (Wong et al. 2006). 
The leaves are well known for the treatment of 
various diseases such as diarrhea, hypertension, gastritis, 
hypercholesterolemia and diabetes mellitus (Sumono & 
Agustin 2008; Khan et al. 2009; Ismail & Wan Ahmad 
2019). Extracts of the leaves have been reported to exhibit 
anti-hypertensive effect (Ismail et al. 2013), antifungal 
activity (Kusuma et al. 2019), antibacterial activity 
(Grosvenor et al. 1995) and antitumor activity (Ali et al. 
2000). However, the hydromethanolic extract of this plant 
has been shown to have weak antibacterial and cytotoxic 
activities on 4T1 and MCF-7 mammary carcinoma cells 
(Nordin et al. 2019). Studies of antioxidant activities of S. 
polyanthum have also been reported (Wong et al. 2006; 
Kusuma et al. 2011; Safriani et al. 2015). However, no 
studies have been reported on possible nephroprotective 
effects in hypertensive induced chronic kidney disease. 
The aim of this study was therefore to determine the 
nephroprotective effects of aqueous extracts of S. 




DPPH was purchased from Friendemann Schmidt, 
Australia, Gallic acid from Sigma-Aldrich, China, 
Quercetin and Glacial acetic acid from Sigma-Aldrich, 
Germany, 2,4,6-tris(2-pyridyl)-1,3,5-triazine (TPTZ) 
from Sigma-Aldrich, Switzerland, Folin-Ciocalteau (F-C) 
reagent from Sigma-Aldrich, USA, Losartan from Merck 
Sharp & Dohme Ltd., United Kingdom. McDowel Trump 
fixative from Merck, USA. All other chemicals were of 
the highest analytical grade available from local suppliers. 
PREPARATION OF AQUEOUS EXTRACT OF 
SYZYGIUM POLYANTHUM
The leaves of S. polyanthum were collected at District of 
Kota Bharu, Kelantan, Malaysia. The plant was identified 
and authenticated by a botanist, Dr. Richard Chung from 
Forest Research Institute Malaysia (FRIM). The voucher 
specimen of dried leaves was then deposited in FRIM 
herbarium with the identification number: PID-171011-10. 
The cleaned leaves were dried in an incubator at 50°C for 
three consecutive days until constant weigh was achieved. 
The dried leaves were ground into powder using laboratory 
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grinder. An aqueous extract of S. polyanthum (AESP) was 
prepared by using ultrasound-assisted extraction technique. 
There were three cycles involved in the process of 
extraction. Sample of 200 g of the plant powder was boiled 
three times with 400 mL, 250 ml and 150 ml of distilled 
water at 80°C. For each cycle, the mixture was boiled for 30 
minutes, stirred thoroughly, sonicated for 30 minutes and 
filtered via Whattman paper No. 1. The resultant filtered 
extract was frozen overnight at -20°C before lyophilized 
in a freeze-dryer. The yields obtained as AESP were kept 
in the -20°C refrigerator for phytochemical analysis and 
antioxidant activity.
PHYTOCHEMICAL ANALYSIS
Phytochemical analysis of AESP was performed using 
colorimetric method to screen the presence of phenolics, 
flavonoids, alkaloids, terpenoids, tannins, saponins, 
steroids, glycosides, cardiac glycosides, quinones, 
resins, anthraquinone, xanthoproteins and coumarins. A 
sample of AESP was dissolved in distilled water with a 
minimum amount of solvent adequate for a solution. The 
identification of phytochemical groups was performed 
using previous standardized methods to evaluate the 
presence for phenolics, flavonoids, tannins, steroids (Doss 
2009), alkaloids, anthraquinone, coumarins, saponins, 
quinones and glycosides (Gul et al. 2017), and terpenoids, 
cardiac glycosides, resins and xanthoproteins (Ganesh & 
Vennila 2011).
TOTAL PHENOLIC AND FLAVONOID 
CONTENTS
Total phenolic and flavonoid contents were done to assess 
the total content of both compounds in the extracts. The 
total phenolic contents in AESP was estimated by using 
Folin-Ciocalteau colorimetric method (Kaur et al. 2008). 
In this study, gallic acid was chosen as the reference 
standard of total phenols compound for construction of the 
calibration curve. Gallic acid stock solution (1 mg/mL) was 
prepared by dissolving 5 mg gallic acid in 5 mL distilled 
water. Then, six different concentrations of standard gallic 
acid were subsequently prepared using distilled water 
(50–300 µg/mL). An amount of 200 µL of each diluted 
standard gallic acid and 200 µl of 1 mg/mL extract were 
added separately into the test tubes followed by addition 
of 800 µL distilled water. Then, 500 µL of 10% (w/v) 
Folin–Ciocalteau reagent was added into each tube. After 
5 minutes, the solution was mixed with 1.5 mL of 20% 
w/v sodium carbonate and incubated at room temperature 
for 2 hours in the dark. The absorbance was measured at 
765 nm against the reagent blank using spectrophotometer. 
The determinations were conducted in triplicates to obtain 
a consistent result. The total phenolic content of the AESP 
was calculated as mg gallic acid equivalents (mg GAE/ 1 
g of the dry extract).
The total flavonoid contents in AESP was measured 
by using aluminium colorimetric method (Kamtekar et al. 
2014). Quercetin that has high constituents of flavonoid 
compounds, was chosen as the reference standard 
for construction of the calibration curve. Quercetin 
stock solution (1 mg/mL) was prepared by dissolving 
5 mg quercetin in 5 mL methanol. Then, six different 
concentrations of standard quercetin (50–300 µg/mL) 
were prepared. 1 mL of each diluted standard quercetin 
and 1 mL of 1 mg/mL extract were separately pipetted 
into the test tubes followed by addition of 4 mL distilled 
water. Subsequently, 0.3 mL of 10% (w/v) sodium nitrate 
solution was added into each tube and allowed to stand 
for 5 minutes. Then, 0.3 mL of 10 % (w/v) aluminium 
chloride solution was added and the reaction mixtures 
were left for 1 minute. Later, 2 mL of 1 M sodium 
hydroxide was added and transferred into the cuvette and 
the absorbance was measured at the wavelength of 420 nm 
using spectrophotometer. All determinations were done 
in triplicates. The total flavonoid contents of the aqueous 
extract (AESP) was calculated as mg quercetin equivalents 
(mg QE/1g of dry extract).
IN VITRO ANTIOXIDANT ACTIVITY
The in vitro antioxidant activities of the extract were 
assessed by using ferric reducing assay and free radical 
scavenging in the present study. Ferric reducing antioxidant 
power (FRAP) Assay: The FRAP response was determined 
by using previous method (Rajurkar & Hande 2011). The 
principle is based on the reduction of ferric tripyridyl 
triazine (Fe3+ TPTZ) complex to a blue-colored ferrous 
(Fe2+). The ferrous sulphate stock solution (5 mM) was 
firstly diluted into six different standard dilutions (0.5–
3 mM) using distilled water accordingly. An amount of 50 
µL of each diluted standard ferrous sulphate, 50 µl of 1 mg/
mL extract and 50 µL of 1 mg/mL of ascorbic acid (positive 
control) were separately added into the test tubes. Then, 150 
µL distilled water was added followed by 1.5 mL FRAP 
reagent. The FRAP reagent was prepared freshly by mixing 
300 mM acetate buffer pH 3.6, 10 mM TPTZ in 40 mM 
HCl, and 20 mM FeCl3.6H20 in the volume ratio 10:1:1. 
The mixtures were mixed well and immediately incubated 
in the ambient room for 30 minutes. The absorbance of 
the mixtures was measured at the wavelength of 593 nm 
using spectrophotometer against the reagent blank. All 
determinations were conducted in triplicates. A calibration 
curve was then generated by plotting the mean absorbance 
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versus the standard ferrous sulphate (0.5-3.0 mM). The 
reducing ability of AESP was expressed as mM ferrous 
equivalents (mM FE / 1 mg of the dry extract).
DPPH Radical Scavenging Assay: In this study, 
gallic acid was chosen as the reference standard for 
the construction of calibration curve and the method 
was performed based on the previous study (Sharma & 
Bhat 2009). Both standard gallic acid and AESP stock 
solution (1 mg/mL each) were prepared. Briefly, 2 mL 
of each diluted standard gallic acid and 2 mL of each 
diluted extract were separately added into the test tubes. 
An amount of 2 mL 0.4 mM DPPH which was diluted 
in methanol was added into each tube mixed thoroughly 
and allowed to stand for 30 minutes. The absorbance 
of the mixtures was measured at the wavelength of 517 
nm using spectrophotometer against reagent blank. As a 
remark, 2 mL of distilled water and 2 mL of methanol 
was served as the blank solution. Three independent tests 
were performed, and the mean absorbance was recorded. 
The percentage of DPPH scavenging activity for both 
samples were determined. 
HIGH PERFORMANCE LIQUID 
CHROMATOGRAPHY
Quantification of the gallic acid was done using high 
performance liquid chromatography (HPLC) technique 
by using Waters Delta 600 with 600 Controller linked to 
a Waters 996 photodiode array detector (Milford, MA, 
USA). For chromatographic analysis, a reversed-phase 
C18 column with length of 4.6 mm i.d x 250 mm was used. 
Briefly, 10 mg of AESP powder was dissolved in 1 mL of 
methanol and filtered using 0.45 µm of syringe filter. The 
mobile phase was a gradient prepared from 0.1% (v/v) 
aqueous formic acid in HPLC-grade water (component 
A) and acetonitrile (component B). A gradient was used 
as 0-12 min, 15% B; 12-22 min, 25% B; 22-25 min, 25% 
B and 25-35 min, 15% B. Throughout the analysis period, 
the flow rate was maintained at 1.0 mL/min while the 
injection volume was maintained at 10 μl. At the same 
time, gallic acid with concentration of 100 µg/mL was 
run as a standard. 
The analyses were recorded at specific wavelength 
(280 nm) using photodiode array detector with three 
replicates. Six serial concentrations of gallic acid (40, 
60, 80, 100, 120, and 140 µg/mL) were run. A calibration 
curve was then generated by plotting the mean absorbance 
versus the standard gallic acid concentrations. The 
concentrations of gallic acid in AESP were then calculated 
and estimated based on the peak areas of AESP in the 
chromatograms and the linear equation obtained from 
the standard curve.
ANIMALS
Fifty male spontaneously hypertensive rats (SHR) and 
10 male Wistar Kyoto rats (WKY) age 8 weeks (200-
250 g) were obtained from Animal and Research Centre 
(ARASC), Universiti Sains Malaysia, Kubang Kerian, 
Kelantan, Malaysia. Animals were kept individually 
in a standard polypropylene cage with a constant 
temperature at 23 ± 1 °C with 12-hour light-dark 
cycle. The procedures and protocols were approved by 
Animal Ethic Committee of Universiti Sains Malaysia 
(USM/ Animal Ethics Approval/ 2016 (102) (757)) in 
accordance with the institutional guidelines. Adequate 
measures were taken to minimize pain or discomfort 
to the rats. Rats were acclimatized for 7 days and were 
administered a standard Altromin pellet imported from 
Germany by Sterling Ascent, Malaysia with water ad 
libitum.
EXPERIMENTAL DESIGN
Ten WKY rats were used as normal control group (WKY). 
Fifty SHR rats were randomly divided into five groups (n 
= 10/group); Untreated SHR (received distilled water), 
Losartan treated (received Losartan at 20 mg/kg), AESP 
1500 mg/kg (received AESP at 1500 mg/kg), AESP 1750 
mg/kg (received AESP 1750 mg/kg) and AESP 2250 mg/
kg (received AESP at 2250 mg/kg). Hypertension starts to 
develop in SHR at 5–6 weeks of age and blood pressure 
plateaus at approximately 50–60 days (Dickhout & Lee 
1997), thus we have chosen rats at 8 weeks of age in 
this study. Untreated SHR represents a model of chronic 
kidney disease secondary to hypertension. SHR is a good 
model for studying human essential hypertension whereby 
proteinuria begins to increase at 6 weeks of age in male 
SHR and increases linearly up to 70 weeks of age (Yang 
et al. 2010). In addition, this model demonstrated the 
presence of glomerulosclerosis and interstitial fibrosis 
starting between 40 and 50 weeks with the GFR decreases 
by 20% to 30% at 14 to 15 and 30 to 32 weeks of age, 
respectively. All rats received normal rat chow pellets and 
water ad libitum. Distilled water, Losartan and AESP were 
administered via oral gavage for 12 weeks. Systolic blood 
pressure (SBP) was measured bi-weekly using a tail-cuff 
method (LabQuip, USA) for 12 weeks. Animals were 
euthanized with 100 mg/kg sodium pentobarbitone via 
intraperitoneal injection. Blood was collected via cardiac 
puncture for the measurement of biochemical parameters, 
full blood count (FBC) and oxidative stress parameters. 
Kidney was isolated, cleaned from adherent fats and 
connective tissues for histological study using scanning 
electron microscope (SEM).
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MEASUREMENT OF BIOCHEMICAL 
PARAMETERS
Blood samples for the measurement of biochemical 
parameters (Blood urea nitrogen (BUN) and serum 
electrolytes) and full blood count (FBC) were sent to B.P. 
Clinical Lab Sdn. Bhd., Kota Bharu, Kelantan. We were 
provided a plain tube for the measurement of BUN and 
serum electrolytes, and a tube contained anticoagulant 
EDTA for measurement of FBC to stop its natural clotting. 
A volume of 3 mL of whole blood was added into each 
tube. FBC was measured in whole blood. 
MEASUREMENT OF OXIDATIVE STRESS 
MARKERS
Oxidative stress markers: malondialdehyde (MDA), total 
antioxidant capacity (TAC), superoxide dismutase (SOD) 
and catalase (CAT) were measured in serum. MDA was 
measured by commercially available kits from Northwest 
Life Sciences Specialties, Washington, USA. TAC, SOD 
and CAT were determined by commercially available kits 
from Bioassay Systems, California, USA.
ULTRASTRUCTURE OF KIDNEY
The ultrastructure of kidney was observed using scanning 
electron microscope (SEM). One mm3 segment of kidney 
was used in this experiment, where it is fixed in McDowel-
Trump at 4°C for 4- 24 hours (Ramli et al. 2017). Sample 
was washed with 0.1 M phosphate buffer for 3 times with 
10 minutes for each change. Then, it was post-fixed and 
incubated at 4°C in 1% osmium tetroxide for 2 hours. 
Sample was then washed with 0.1 M phosphate buffer for 3 
times with 10 minutes for each change. Sample underwent 
dehydration process in a series of ascending acetone 
concentration (35%, 50%, 75%, 95% and 100%) for 10 
minutes each except 15 minutes for 100% acetone. Then, 
it was leaved to air dried in critical point dryer instrument 
(Quantum Technologies, E3000). The dried specimen was 
then mounted onto nickel stubs, spatter-coated with gold 
and platinum, and observed under SEM (FEI Quanta 450 
Scanning Electron Microscope, Thermo Fisher Scientific, 
USA).
STATISTICAL ANALYSIS
GraphPad Prism (version 8.0 for Windows, GraphPad 
Software, La Jolla California USA) was used to analyze 
the data. The normality test was performed to determine 
whether the data distribution was normally distributed. 
One-way analysis of variance (ANOVA) test was used 
and followed by Tukey’s post-hoc test for multiple 
comparisons. SBP was analyzed using repeated-measures 
analysis of variance (ANOVA). Values are expressed as 
means (with standard deviations). All tests were two-tailed 
and the level of significance was set at p<0.05.
RESULTS
PHYTOCHEMICAL ANALYSES
The phytochemical analyses of AESP revealed the 
presence of multiple compounds as shown in Table 1. The 
findings indicate the presence of bioactive components 
in the AESP.
ANTIOXIDANT ACTIVITY
AESP showed high total phenolic and flavonoid contents 
as well as high antioxidant activities from ferric reducing 
antioxidant power (FRAP) and DPPH (2,2-diphenyl-1-
picrylhydrazyl) assays when compared with the standard 
reference as shown in Table 2. The total phenolic content 
in AESP was 232.806 (0.3867) mg gallic acid equivalent 
(GAE)/gram of dry extract), which suggests AESP has high 
phenolic contents (Perumal et al. 2012). The total flavonoid 
content in AESP was 100.260 (1.3354) mg quercetin (QE)/
gram of dry extract), which suggests AESP is a good source 
of flavonoid contents (Perumal et al. 2012). The ferric ion-
reducing activity of AESP was 5.274 (0.16) mM FE/ mg 
of dry extract while the ascorbic acid was 6.675 (0.224). 
The activity of AESP was comparable to ascorbic acid. 
AESP also shows a strong DPPH scavenging activity of 
(93.57 (0.203) %) which was comparable to gallic acid 
(93.87 (1.44) %). 
GALLIC ACID QUANTIFICATION 
Figure 1 shows high performance liquid chromatography 
(HPLC) chromatogram of AESP at wavelength of 280 nm. 
Multiple peaks (compounds) were observed which were 
eluted at different time, t= 2.801, 3.899, 4.778, 8.731, 
10.402 and 15.962 minutes, respectively. The highest peak 
was observed at t= 3.899 minutes, that is similar elution 
time with typical chromatogram of standard gallic acid (t= 
3.899 minutes). Hence, the results strongly suggest gallic 
acid might present in AESP with the highest detection.
SYSTOLIC BLOOD PRESSURE
Figure 2 shows the changes of bi-weekly systolic blood 
pressure (SBP) for 12 weeks in all groups. The mean 
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SBP of untreated SHR was significantly higher when 
compared to WKY throughout the study period. There 
was a significant main effect of time (F4.622, 249.6 = 
915.2; p<0.0001), signify a differences in the SBP among 
the different time points from 2 weeks to 12 weeks. There 
was also a significant main effect of treatment (F30, 324 
= 123.0; p<0.0001) whereby SHR treated rats displayed 
significantly decreased SBP compared to untreated SHR. 
In addition, SBP from AESP 1750 mg/kg group and 
AESP 2250 mg/kg group were normalized at week 10, 
and by week 12, SBP from all AESP treated groups were 
normalized. 
















Note: AESP: Aqueous extract of S. polyanthum leaves, “+”: Presence of class constituent and “–”: Absence of class constituent




Content (mg QE gˉ1)
FRAP Assay 
mM FE/ mg )
DPPH Assay
(% inhibition)
AESP 232.806 (0.3867) 100.260 (1.3354) 5.274 (0.16) 93.57 (0.203)




Note: AESP, Aqueous extract of S. polyanthum leaves; DPPH, 2-2-diphenyl-2-picrylhydrazyl; FRAP, ferric reducing antioxidant 
power. The measurement was performed in triplicate. All values are shown in mean (standard deviation)
FIGURE 1. HPLC chromatogram of AESP at wavelength of 280 nm with standard reference gallic acid.
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THE EFFECTS OF AESP ON RENAL 
PARAMETERS
Blood urea nitrogen (BUN), creatinine, uric acid and 
potassium were significantly higher in untreated SHR when 
compared to WKY group (Table 3). Losartan and AESP 
supplementation at all doses significantly reduced the levels 
of BUN, creatinine and uric acid. However, only treatment 
with AESP at 1750 mg/kg and 2250 mg/kg significantly 
reduced the potassium level compared to untreated SHR. 
There were no significant differences in levels of sodium 
between the groups. 
THE EFFECTS OF AESP ON OXIDATIVE  
STRESS MARKERS
Table 4 shows the results of oxidative stress markers 
in the serum. MDA levels were significantly higher in 
the untreated SHR compared to the WKY group. All 
the treatment groups showed significant lower of MDA 
levels compared to untreated SHR. SOD activities were 
significantly lower in untreated SHR compared to the 
WKY group. Treatment with Losartan and AESP (1500 
mg/kg and 1750 mg/kg) showed significant increased 
SOD activities compared to untreated SHR. Meanwhile, 
there was no significant difference in SOD levels between 
AESP at 2250 mg/kg and untreated SHR. There were 
no significant differences in the levels of TAC and CAT 
between the groups.
THE EFFECTS OF AESP ON FULL BLOOD 
COUNT
There was no significant difference in each parameter 
between the groups (Table 5). 
ULTRASTRUCTURE OF KIDNEY
The ultrastructure of kidney was examined using scanning 
electron microscope (SEM). Figure 3 demonstrates the 
images of rat’s kidney from all groups. The kidney was 
viewed under magnification of 2500x and 10,000x. In 
WKY group, at 2500x magnification (a), 3D image of 
glomerulus was viewed. The glomerulus was situated 
within the capsule and well-surrounded by glomerular 
membrane. It was illustrated as tight ball capillaries 
surrounded by podocytes. The podocytes exhibit as 
normal foot processes, which arranged in parallel, longer 
in size and show numerous foot-like radiating surrounds 
the capillary loop (known as pedicels). There were (b) 
no distortion or fusion of podocytes was identified in the 
10,000X magnification. 
In contrary, in untreated SHR group, the glomerulus 
appearance was slightly distorted and shrunk (c). Whereas 
the podocytes appeared large in size and blunted. The foot 
process was also irregular in thickness and some started 
to detach from the capillary loop. The pedicels displayed 
as short, tortuous and not in parallel arrangement (d). On 
the other hand, in the kidney of the Losartan-treated rat, 
1500 mg/kg, 1750 mg/kg and 2250 mg/kg AESP-treated 
rat, there were marked improvement of the glomerular 
appearance and size. The Bowman’s space looked more 
defined and the podocytes showed regular in arrangement 
(e), (g), (i), (k). All treatment groups also showed normal 
appearance of podocytes; illustrating as parallel, longer and 
thin in size (f), (j), (l) which similar like podocytes structure 
of WKY except for 1500 mg/kg AESP (h). In rat treated 
with 1500 mg/kg AESP, the foot process is still a bit large; 
but less when compared to the untreated-SHR group (d).
DISCUSSION
Herbal supplements have become more commonly used 
recently due to their lower side effects in the protection and 
treatment of certain diseases. In this study, we determined 
the phytochemical constituents of the aqueous extract of 
S. polyanthum (AESP) and the nephroprotective effects in 
the hypertensive animal model. For the first time, we have 
shown that AESP can ameliorate hypertensive induced 
chronic kidney disease (CKD) and oxidative stress. In 
addition, CKD resulted in functional disturbances and 
cellular damages in the kidneys are reduced by AESP 
supplementation. We demonstrated various compounds 
in AESP, including phenolics, flavonoids and alkaloids, as 
shown in Table 1. Previous studies reported that ethanol 
extract of S. polyanthum contains flavonoid, tannin, 
triterpenoid, carbohydrate, alkaloid and steroid (Kusuma 
et al. 2011), while in methanol extract, tannins, glycosides, 
flavonoids and alkaloids have been detected (Widyawati et 
al. 2015). Total phenolic and flavonoid content as well as 
antioxidant activities were also high in AESP. 
After 12 weeks of daily administration of AESP, the 
systolic blood pressure (SBP) decreased significantly 
in all AESP treated groups when compared to untreated 
group. In fact, SBP levels of all AESP treated groups 
were normalized at the end of the study, suggesting that 
AESP is a potential anti-hypertensive agent. Importantly, 
it was reported that aqueous and methanolic extracts of S. 
polyanthum leaves significantly lowered blood pressure in 
spontaneously hypertensive rats (SHR) when administered 
intravenously (Ismail et al. 2013), which support the 
present study. There is considerable evidence supporting 
the view that dietary intake of antioxidants and polyphenols 
may have an effect of primary prevention or reduction of 
FIGURE 2. Effects of aqueous extract of S. polyanthum leaves (AESP) on systolic blood pressure in SHR during the treatment 
period of 12 weeks. Each group consisted of 10 rats (n=10). WKY, Wistar-Kyoto rats; Losartan treated, SHR treated with Losartan 
20 mg/kg;  AESP 1500 mg/kg, SHR treated with AESP 1500 mg/kg; AESP 1750 mg/kg, SHR treated with AESP 1750 mg/kg; 
AESP 2250 mg/kg, SHR treated with AESP 2500 mg/kg. *p<0.001 compared to untreated SHR.
TABLE 3. The effects of AESP on renal parameters
Group BUN (mmol/L) Cr (µmol/L) UA (µmol/L) K (mmol/L) Na (mmol/L)
WKY 6.80 (0.70) 44.02 (2.47) 111.1 (33.79) 5.7 (0.35) 140.6 (0.89)
Untreated SHR 10.97*** (0.80) 56.10*** (5.95) 278.1*** (66.70) 6.52* (0.63) 139.4 (1.68)
Losartan treated 9.13**,# (1.28) 43.98### (3.74) 107.7### (15.44) 5.82 (0.35) 140.2 (1.79)
AESP 1500 mg/kg 7.35### (0.96) 39.42### (1.17) 119.6### (14.04) 5.78 (0.33) 139.0 (1.00)
AESP 1750 mg/kg 7.72### (0.87) 48.77# (2.69) 100.5### (14.28) 5.36## (0.36) 139.2 (0.84)
AESP 2250 mg/kg 7.86### (0.48) 48.56# (1.73) 83.72### (20.29) 5.22### (0.15) 140.0 (2.34)
Note: Data are presented as mean (with standard deviation), n=10 per group. WKY, Wistar-Kyoto rats; Losartan treated, SHR 
treated with Losartan 20 mg/kg;  AESP 1500 mg/kg, SHR treated with AESP 1500 mg/kg; AESP 1750 mg/kg, SHR treated with 
AESP 1750 mg/kg; AESP 2250 mg/kg, SHR treated with AESP 2500 mg/kg. *p<0.05, **p<0.01 and ***p<0.001 compared to 
WKY; #p<0.05, #p<0.01 and ###p<0.001 compared to untreated SHR (one way ANOVA followed by Tukey’s post-hoc test).
TABLE 4. The effects of AESP on oxidative stress markers
Group MDA (nmol/mg Protein) TAC (µM Trolox Equivalents) SOD (U/mg Protein) CAT (U/mg Protein)
WKY 5.50 (0.71) 233.5 (50.55) 2.83 (0.38) 13.84 (0.11)
Untreated SHR 13.15*** (1.54) 172.5 (7.69) 0.57*** (0.25) 13.93 (0.09)
Losartan treated 6.56### (1.02) 206.9 (14.50) 3.00### (0.21) 13.81 (0.18)
AESP 1500 mg/kg 8.65# (0.51) 219.2 (17.49) 2.21### (0.51) 13.85 (0.05)
AESP 1750 mg/kg 8.85# (0.66) 233.0 (43.83) 2.94### (0.21) 13.82 (0.17)
AESP 2250 mg/kg 6.33### (1.35) 225.1 (22.78) 1.24** (0.07) 13.94 (0.05)
Note: Data are presented as mean (with standard deviation), n=10 per group. WKY, Wistar-Kyoto rats; Losartan treated, SHR 
treated with Losartan 20 mg/kg;  AESP 1500 mg/kg, SHR treated with AESP 1500 mg/kg; AESP 1750 mg/kg, SHR treated with 
AESP 1750 mg/kg; AESP 2250 mg/kg, SHR treated with AESP 2500 mg/kg. **p<0.01 and ***p<0.001 compared to WKY; 
#p<0.05, ###p<0.001 compared to untreated SHR (one-way ANOVA followed by Tukey’s post-hoc test).
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TABLE 5. The effects of AESP on full blood count








Lymphocycte (%) Platelet Counts 
(×109/L)
WKY 8.67 (0.17) 151.0 (2.08) 0.47 (0.01) 7.30 (0.23) 57.7 (0.33) 685.7 (5.67)
Untreated SHR 9.23 (0.12) 145.7 (2.40) 0.46 (0.01) 6.67 (0.72) 66.0 (2.00) 868.7 (26.59)
Losartan treated 9.05 (0.09) 144.7 (1.20) 0.46 (0.01) 6.90 (0.21) 54.3 (2.60) 827.0 (31.10)
AESP 1500 mg/kg 9.47 (0.09) 151.7 (0.33) 0.47 (0.01) 7.13 (0.22) 58.0 (6.66) 766.3 (23.56)
AESP 1750 mg/kg 8.73 (0.27) 141.7 (1.67) 0.44 (0.01) 7.47 (0.64) 63.3 (3.28) 803.7 (59.83)
AESP 2250 mg/kg 9.03 (0.09) 143.0 (1.73) 0.45 (0.01) 7.47 (0.26) 64.3 (2.33) 780.3 (78.67)
Note: Data are presented as mean (with standard deviation), n=10 per group. WKY, Wistar-Kyoto rats; Losartan treated, SHR 
treated with Losartan 20 mg/kg;  AESP 1500 mg/kg, SHR treated with AESP 1500 mg/kg; AESP 1750 mg/kg, SHR treated with 
AESP 1750 mg/kg; AESP 2250 mg/kg, SHR treated with AESP 2500 mg/kg (one-way ANOVA followed by Tukey’s post hoc test).
FIGURE 3. Scanning electron microscopic images of the interior of an adult rat glomerulus showing interdigitating foot processes 
(FP) encompassing capillary loops and (P) podocyte cell body from WKY (a-b) and untreated SHR (c-d) under 2500x and 10000x 
respectively. In WKY rat, a regular arrangement with parallel, longer and thin podocytes are seen. In SHR rat, the podocytes appear 
large in size and blunted, the foot process is irregular in thickness and some started to detach from the capillary loop. There is also 
loose podocyte seen (red arrow).
hypertension (Redon et al. 2003), which further support 
AESP is potential to reduce blood pressure. 
Kidney disease is considered to be a cause and 
consequence of hypertension. In the present study, it is 
proposed that the CKD is a consequence of hypertension 
of at least for 12 weeks, which is considered as chronic 
duration (Mohammed Ali et al. 2017). Although systemic 
hypertension is linked to glomerular hypertension, the 
exact mechanism by which glomerular hypertension 
induces glomerular injury is not clear. The features of 
CKD are well demonstrated by the biochemical and 
histopathological changes in untreated SHR group. The 
abnormal biochemical changes include increase in serum 
concentrations of creatinine, urea-nitrogen and uric acid 
indicated a decline in kidney function (Mohamadi Yarijani 
et al. 2019). Reduction of renal function in CKD is may 
be due to glomerular hypertrophy (Varatharajan et al. 
2017), mesangial cells proliferation and their contraction 
(Martinez-Salgado et al. 2007), and increased resistance of 
renal vessels (Randjelovic et al. 2017). Kidney expresses 
its own renin–angiotensin–aldosterone system (RAAS) 
and inappropriate intraglomerular RAAS activation 
may decrease the renal function, such as in hypertensive 
nephropathy, diabetic nephropathy and glomerulonephritis 
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(Siragy & Carey 2010). Interestingly, the levels of renal 
parameters were improved in all SHR treated groups, 
Losartan and AESP, with exception of potassium levels 
which reduced significantly only in AESP 1750 mg/kg and 
2250 mg/kg groups. 
The precise mechanisms for hypertension and 
associated renal damage are not well clarified. In order to 
further assess the possible underlying mechanism of CKD 
in hypertension, we measured oxidative stress markers. 
Oxidative stress occurs when there is an imbalance 
between the generation of reactive oxygen species (ROS) 
and the antioxidant defense systems, and it is believed to 
be involved in many types of disease processes. In people 
with hypertension, ROS are elevated, while antioxidant 
capacity is decreased and many of which develop end-
stage renal disease (ESRD) (Manning et al. 2005). ROS 
are harmful to cells and tissues, thus a proper balance 
between ROS production and removal is required to 
maintain normal biological conditions (Honda et al. 2019). 
Increased ROS production decreased nitric oxide (NO) 
levels and antioxidant bioavailability have been reported 
in hypertensive patients and various animal models of 
hypertension (Redon et al. 2003; Tanito et al. 2004). In the 
vascular wall, ROS is primarily derived from nicotinamide 
adenine dinucleotide phosphate (NADPH) oxidase that 
stimulated by hormones, including angiotensin II (AT-II) 
and endothelin-1 (ET-1), and ROS is also generated by 
increased mechanical stimuli on the vascular wall (Rodrigo 
& Rivera 2002). 
Evidence suggests that there is a decrease in enzymatic 
antioxidant in hypertensive humans and animal models of 
hypertension, resulting in reduced antioxidant defenses 
(Zhou et al. 2006; Lee et al. 2010). For example, a reduction 
in superoxide dismutase (SOD) and glutathione peroxidase 
(GPx) activities have been demonstrated in newly 
diagnosed and untreated hypertension that is inversely 
correlated with blood pressure (Baradaran et al. 2014). 
Increased levels of MDA and decreased SOD, catalase 
(CAT) and glutathione peroxidase GPX were detected in 
hypertensive patients compared to normal subjects (Ahmad 
et al. 2013). In untreated SHR, there were increased serum 
levels of malondialdehyde (MDA), a byproduct derived 
from lipid peroxidation. In addition, the levels of SOD were 
significantly lower in this group, which further support 
oxidative stress as a possible cause of kidney disease in this 
study, which is consistent with previous study (Manning 
et al. 2005). In AESP treated groups, MDA levels were 
significantly lower compared to untreated SHR, and 
therefore AESP was able to ameliorate oxidative stress, 
which is comparable to Losartan. Significant increased 
SOD has been observed in AESP treated groups that may 
be attributed to lower levels of MDA in these groups. 
However, AESP at 2250 mg/kg did not increase the activity 
of SOD, in fact the level was significantly lower compared 
to WKY group. 
The improvement in oxidant/antioxidant status may be 
attributed to its phytochemical compounds, gallic acid as 
demonstrated by the HPLC analysis. The therapeutic effects 
of gallic acid and its derivatives have been implicated in 
various diseases due to its biological and pharmacological 
activities, including antioxidant, antimicrobial, and anti-
inflammatory (Kahkeshani et al. 2019). In rat models 
of myocardial infarction, pretreatment with gallic acid 
increases the activity of antioxidant enzymes, such as SOD, 
FIGURE 4. Scanning electron microscopic images of the interior of an adult rat glomerulus showing interdigitating foot processes 
(FP) encompassing capillary loops and (P) podocyte cell body from Losartan treated (e-f), AESP 1500mg/kg (g-h), AESP 1750 mg/
kg (i-j) and AESP 2250 mg/kg (k-l) under 2500x and 10000x respectively. There are marked improvement of the podocytes, which 
appear parallel, longer and thin in size. However, in 1500 mg/kg AESP group, the foot process is still a bit large (h).  
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CAT, glutathione transferase (GST), and GPx, also non-
enzymatic antioxidant agents, such as glutathione (GSH), 
vitamin C, and vitamin E (Priscilla et al. 2009).
In scanning electron microscopy study, renal 
histology in untreated SHR revealed features of renal 
damage, including distorted and shrunk glomerulus 
with irregular thickness of the foot process (Ramli et al. 
2017). The main pathological changes associated with 
chronic kidney disease include glomerulosclerosis and 
tubulointerstitial fibrosis, which result in a loss of normal 
renal architecture (Mullins et al. 2016). In the present study, 
we demonstrated that 12 weeks of hypertension induced 
renal damage. Renal damage secondary to hypertension is 
usually affects the small renal arteries of the glomerulus 
(Mule et al. 2008) and the degree of the damage increases 
with the duration of hypertension (Wang et al. 2013). In 
hypertensive renal damage, the capillary plexus collapses 
and the basement membrane shrinks, leading to renal 
ischemia and glomerular ischemia, which demonstrated 
as a ball sclerosis, the glomerular sclerosis (Wang et al. 
2013). Study in mice showed a larger glomerular size with 
widened and effaced foot processes in hypertensive group 
(Li et al. 2019). Podocytes, the terminally differentiated 
cells of glomerular filtration barrier, play an active role 
in preventing plasma proteins from entering the urinary 
ultrafiltrate. In this study, the podocytes of untreated SHR 
were large in size and blunted. Podocytes are the main 
targets of various soluble and cellular products, including 
ROS, toxins, complements and antibodies (Reiser & 
Altintas 2016) that may support the podocytes changes 
in this study. 
Meanwhile, foot processes interdigitate with foot 
processes from adjacent podocytes to form a network of 
narrow and uniform gaps. When podocytes are injured, 
the elaborate structure of podocytes is physically altered, 
i.e. ‘foot process effacement’, which is found in many 
proteinuric kidney diseases (Reiser & Altintas 2016). In 
the present study, the foot process in the untreated SHR 
group was irregular in thickness and some started to detach 
from the capillary loop. Interestingly, there were marked 
improvement of the glomerular, the Bowman’s space 
and podocytes appearance in SHR treated with Losartan 
and AESP at 1750 mg/kg and 2250 mg/kg. However, in 
1500 mg/kg AESP group, although the glomerular and 
the Bowman’s space appeared normal, the foot process is 
still a bit large; but less when compared to the untreated-
SHR group. Previously, we demonstrated that 4 weeks 
administration of 2000 mg/kg methanolic extract of S. 
polyanthum (MESP) leaves to SHR rats improved the 
histological changes of renal structure when compared to 
untreated SHR (Ramli et al. 2017).
Appropriate anti-hypertensive agent reduces the 
abnormalities of renal outcome in kidney disease (Judd & 
Calhoun 2015). For example, the use of Angiotensin II type 
1 receptor (AT1R) antagonist (Losartan) on SHR rats with 
ischemic acute renal failure (ARF) have been demonstrated 
to improve blood pressure, renal function and structure 
(Ivanov et al. 2014). Treatment with Losartan induced a 
significant increase of creatinine and urea clearance, and 
reduced cortico-medullary necrosis and tubular dilatation 
in the kidney when compared to untreated SHR with ARF. 
Preventing hypertensive induced CKD is necessary as no 
symptoms shown at early stage of renal damage, the patients 
usually have no symptoms (Wang et al. 2013). Furthermore, 
unlike acute kidney injury, the damage that occurs in the 
chronic kidney disease is irreversible, thus preventing 
disease progression and preserving organ function is 
extremely important (Mohammed Ali et al. 2017). The 
values of hematological parameters were normal and the 
improvement in the biochemical parameters suggested that 
AESP does not toxic to the body. It was reported previously 
that administration of ethanol extract of S. polyanthum did 
not show toxicity on the hematological parameters, renal 
and liver functions (Sumiwi et al. 2019). The findings of 
this study may indicate the potential mechanism of AESP 
as a nephroprotective effects in hypertension.
CONCLUSION
Administration of AESP significantly normalized SBP 
and improved biochemical parameters. Although all 
the AESP treated groups significantly reduced MDA 
levels, only AESP at 1500 mg/kg and 1750 mg/kg were 
able to significantly increase SOD levels compared to 
untreated SHR. Both AESP at 1750 mg/kg and 2250 
mg/kg significantly improved all histological changes 
in renal damage. It is therefore suggested that AESP has 
anti-hypertensive and nephroprotective effects, possibly 
partly due to its phenolic compounds that have high 
antioxidant properties. However, further studies are needed 
to determine the exact molecular mechanisms of action that 
involve in anti-hypertensive and nephroprotective effects.
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